

ANALYSIS IMMUNOSUPPRESSANTS COST PARAMETERS USED IN THE TREATMENT OF PSORIASIS

Maltseva T. I., Simonyan L. S.

Scientific supervisor: PhD, Simonyan L.S.

National University of Pharmacy, Kharkiv, Ukraine

3tanya95@mail.ru

Introduction. Psoriasis – a chronic systemic immuno-mediated disease, which mainly affects the skin and joints. Psoriasis – one of the most common chronic dermatosis, they suffer to 3% of the world population. In Ukraine this nosology affects about 1.5 million people. Keen interest in this disease is associated not only with an increase in the incidence of psoriasis in recent years, but with increasing frequency of severe forms of dermatitis, which often lead to disability.

About 20% of patients with psoriasis have medium-heavy form or heavy form of disease. In the US, about 1.5 million people suffering from moderately severe forms of psoriasis, approximately 30% of patients with psoriasis develop psoriatic arthritis, which often leads to disability.

The urgency of treatment and timely diagnosis is the worldwide prevalence of psoriasis, the lack of domestic production of drugs in the pharmaceutical market, the high risk of morbidity and increased risk of cardiovascular related diseases.

Aim. The research is an analysis of cost factors immunosuppressants used in the treatment of psoriasis.

Materials and methods. We analyzed standardized clinical protocols of medical care to patients with psoriasis, data of the State Register of Medicinal Products of Ukraine, price lists weekly journal "Apteka". It was applied retrospectively, logical, systematic method of analysis.

Results and discussion. According to the ATC classification system, the drugs used in the pharmacotherapy of psoriasis are a group L04 – immunosuppressants. Analysis of state registration as of December 2016 study drugs found that the domestic pharmaceutical market was attended by 77 trade names of drugs based forms of production, namely - L04AA - 29 trade names of drugs, L04AB – 10 kinds of drugs, L04AC - 11, L04AD - 25 and only 2 L04AX trade names. The analysis by the manufacturing companies in the pharmaceutical market, found that the domestic market for 100% of the drug European companies.

Analysis dosage forms of drugs immunosuppressants, revealed that currently on the market there are six forms of medications used for the treatment of psoriasis: capsules, concentrates, lyophilisates, powders, solutions and tablets. The leaders are solid dosage forms, namely 71%.

Analysis of price index growth between 2012-2016. Revealed that agents of

foreign manufacturers lowest prices index was 0.98 during the 2013/2012. The highest price index was marked in the years 2014/2013 - 1.34. Established that from 2012 to 2014 price index increased immunosuppressants drugs growth by 36.73%.

From 2014 there is a gradual decrease of the indices of growth in prices, it may be associated with the stabilization of the exchange rate on the domestic market. For example the cost of the drug Mifortik, coated tablets intestinal-soluble. 180 mg blister, №120, company Novartis Pharma (Switzerland) in 2012 amounted to 1320.36 UAH, And in 2016 given drugs actually increased in price 3 times, this cost was 4,440.87 UAH. According to the analysis of the market price index foreign drugs in the study period observed significant changes in the dynamics of prices for medicines.

Price indices immunosuppressants domestic production of drugs in the pharmaceutical market was also stable. Thus the maximum rate of price index is 1.30 in the period 2015/2014. While for the years 2016/2015 price index amounted to - 1.04. Drugs immunosuppressants domestic production have been on the market only in 2015. Average performance index of price growth in the period 2012-2015 p. Increased by 44.71%, the drug Lefno, coated tablets 20 mg blister, №30, Kusum Farm of the company (Ukraine). The maximum prices for drugs immunosuppressants domestic production was in the 2014/2015 years, and drugs of foreign origin - in 2013/2014 years.

Currently, a decrease in the price index for drugs for the treatment of psoriasis, it may be associated with an increase in the range of medicines and stabilization of exchange rates on the market.

Conclusions. According to the analysis of state registration immunosuppressants drugs used in the treatment of psoriasis in the domestic market was attended by 77 trade names of drugs based forms of production. Analysis by the manufacturer, established that the domestic marks 100% consists of foreign manufactures. The analysis for dosage forms revealed that leaders are solid dosage forms, such as 71% (capsules, tablets, powders and lyophilisates for injection).

Analysis of index of price growth between 2012-2016 revealed that agents of foreign manufacturers lowest prices index was 0.98 during the 2013/2012. The highest price index was marked in the years 2014/2013 - 1.34. Established that since 2012 to 2014 growth of immunosuppressants drugs price index increased by 36.73%. The maximum prices for drugs immunosuppressants domestic production was in the 2014/2015 years, and drugs of foreign origin - in 2013/2014 years.

Currently, a decrease in the price index for drugs for the treatment of psoriasis, it may be associated with an increase in the range of medicines and stabilization of exchange rates on the market.